266 related articles for article (PubMed ID: 26415557)
1. Negative Impact of Unidirectional Host-versus-Graft Killer Cell Immunoglobulin-like Receptor Ligand Mismatch on Transplantation Outcomes after Unmanipulated Haploidentical Peripheral Blood Stem Cell Transplantation for Acute Myeloid Leukemia.
Yahng SA; Jeon YW; Yoon JH; Shin SH; Lee SE; Cho BS; Eom KS; Kim YJ; Lee S; Min CK; Cho SG; Kim DW; Lee JW; Min WS; Kim HJ
Biol Blood Marrow Transplant; 2016 Feb; 22(2):316-323. PubMed ID: 26415557
[TBL] [Abstract][Full Text] [Related]
2. Donor-recipient killer immunoglobulin like receptor (KIR) genotype matching has a protective effect on chronic graft versus host disease and relapse incidence following HLA-identical sibling hematopoietic stem cell transplantation.
Sahin U; Dalva K; Gungor F; Ustun C; Beksac M
Ann Hematol; 2018 Jun; 97(6):1027-1039. PubMed ID: 29549412
[TBL] [Abstract][Full Text] [Related]
3. A well-tolerated regimen of 800 cGy TBI-fludarabine-busulfan-ATG for reliable engraftment after unmanipulated haploidentical peripheral blood stem cell transplantation in adult patients with acute myeloid leukemia.
Yahng SA; Kim JH; Jeon YW; Yoon JH; Shin SH; Lee SE; Cho BS; Eom KS; Kim YJ; Lee S; Min CK; Cho SG; Kim DW; Lee JW; Min WS; Park CW; Kim HJ
Biol Blood Marrow Transplant; 2015 Jan; 21(1):119-29. PubMed ID: 25300871
[TBL] [Abstract][Full Text] [Related]
4. Killer cell immunoglobulin-like receptor ligand mismatching and outcome after haploidentical transplantation with post-transplant cyclophosphamide.
Shimoni A; Labopin M; Lorentino F; Van Lint MT; Koc Y; Gülbas Z; Tischer J; Bruno B; Blaise D; Pioltelli P; Afanasyev B; Ciceri F; Mohty M; Nagler A
Leukemia; 2019 Jan; 33(1):230-239. PubMed ID: 29907809
[TBL] [Abstract][Full Text] [Related]
5. The role of missing killer cell immunoglobulin-like receptor ligands in T cell replete peripheral blood stem cell transplantation from HLA-identical siblings.
Clausen J; Kircher B; Auberger J; Schumacher P; Ulmer H; Hetzenauer G; Wolf D; Gastl G; Nachbaur D
Biol Blood Marrow Transplant; 2010 Feb; 16(2):273-80. PubMed ID: 19857587
[TBL] [Abstract][Full Text] [Related]
6. Prognosis after unmanipulated HLA-haploidentical blood and marrow transplantation is correlated to the numbers of KIR ligands in recipients.
Zhao XY; Huang XJ; Liu KY; Xu LP; Liu DH
Eur J Haematol; 2007 Apr; 78(4):338-46. PubMed ID: 17378893
[TBL] [Abstract][Full Text] [Related]
7. The effect of KIR ligand incompatibility on the outcome of unrelated donor transplantation: a report from the center for international blood and marrow transplant research, the European blood and marrow transplant registry, and the Dutch registry.
Farag SS; Bacigalupo A; Eapen M; Hurley C; Dupont B; Caligiuri MA; Boudreau C; Nelson G; Oudshoorn M; van Rood J; Velardi A; Maiers M; Setterholm M; Confer D; Posch PE; Anasetti C; Kamani N; Miller JS; Weisdorf D; Davies SM;
Biol Blood Marrow Transplant; 2006 Aug; 12(8):876-84. PubMed ID: 16864058
[TBL] [Abstract][Full Text] [Related]
8. Natural Killer Cell Alloreactivity Predicted By Killer Cell Immunoglobulin-Like Receptor Ligand Mismatch Does Not Impact Engraftment in Umbilical Cord Blood and Haploidentical Stem Cell Transplantation.
Otegbeye F; Vina MAF; Wang T; Bolon YT; Lazaryan A; Beitinjaneh A; Bhatt VR; Castillo P; Marsh SGE; Hildebrandt GC; Assal A; Brown VI; Hsu J; Spellman S; de Lima M; Lee SJ
Transplant Cell Ther; 2022 Aug; 28(8):483.e1-483.e7. PubMed ID: 35643351
[TBL] [Abstract][Full Text] [Related]
9. Busulfan dose intensity and outcomes in reduced-intensity allogeneic peripheral blood stem cell transplantation for myelodysplastic syndrome or acute myeloid leukemia.
Chen YB; Coughlin E; Kennedy KF; Alyea EP; Armand P; Attar EC; Ballen KK; Cutler C; Dey BR; Koreth J; McAfee SL; Spitzer TR; Antin JH; Soiffer RJ; Ho VT
Biol Blood Marrow Transplant; 2013 Jun; 19(6):981-7. PubMed ID: 23562738
[TBL] [Abstract][Full Text] [Related]
10. Effects of priming with recombinant human granulocyte colony-stimulating factor on conditioning regimen for high-risk acute myeloid leukemia patients undergoing human leukocyte antigen-haploidentical hematopoietic stem cell transplantation: a multicenter randomized controlled study in southwest China.
Gao L; Wen Q; Chen X; Liu Y; Zhang C; Gao L; Kong P; Zhang Y; Li Y; Liu J; Wang Q; Su Y; Wang C; Wang S; Zeng Y; Sun A; Du X; Zeng D; Liu H; Peng X; Zhang X
Biol Blood Marrow Transplant; 2014 Dec; 20(12):1932-9. PubMed ID: 25109850
[TBL] [Abstract][Full Text] [Related]
11. Haploidentical Natural Killer Cells Infused before Allogeneic Stem Cell Transplantation for Myeloid Malignancies: A Phase I Trial.
Lee DA; Denman CJ; Rondon G; Woodworth G; Chen J; Fisher T; Kaur I; Fernandez-Vina M; Cao K; Ciurea S; Shpall EJ; Champlin RE
Biol Blood Marrow Transplant; 2016 Jul; 22(7):1290-1298. PubMed ID: 27090958
[TBL] [Abstract][Full Text] [Related]
12. Peripheral blood stem cell graft compared to bone marrow after reduced intensity conditioning regimens for acute leukemia: a report from the ALWP of the EBMT.
Savani BN; Labopin M; Blaise D; Niederwieser D; Ciceri F; Ganser A; Arnold R; Afanasyev B; Vigouroux S; Milpied N; Hallek M; Cornelissen JJ; Schwerdtfeger R; Polge E; Baron F; Esteve J; Gorin NC; Schmid C; Giebel S; Mohty M; Nagler A
Haematologica; 2016 Feb; 101(2):256-62. PubMed ID: 26565001
[TBL] [Abstract][Full Text] [Related]
13. A Phase 2 Trial of KIR-Mismatched Unrelated Donor Transplantation Using in Vivo T Cell Depletion with Antithymocyte Globulin in Acute Myelogenous Leukemia: Children's Oncology Group AAML05P1 Study.
Davies SM; Iannone R; Alonzo TA; Wang YC; Gerbing R; Soni S; Kolb EA; Meshinchi S; Orchard PJ; Burns LJ; Shenoy S; Leung W
Biol Blood Marrow Transplant; 2020 Apr; 26(4):712-717. PubMed ID: 31870931
[TBL] [Abstract][Full Text] [Related]
14. Donor killer immunoglobulin-like receptor (KIR) genotype-patient cognate KIR ligand combination and antithymocyte globulin preadministration are critical factors in outcome of HLA-C-KIR ligand-mismatched T cell-replete unrelated bone marrow transplantation.
Yabe T; Matsuo K; Hirayasu K; Kashiwase K; Kawamura-Ishii S; Tanaka H; Ogawa A; Takanashi M; Satake M; Nakajima K; Tokunaga K; Inoko H; Saji H; Ogawa S; Juji T; Sasazuki T; Kodera Y; Morishima Y;
Biol Blood Marrow Transplant; 2008 Jan; 14(1):75-87. PubMed ID: 18158964
[TBL] [Abstract][Full Text] [Related]
15. T cell-depleted partial matched unrelated donor transplant for advanced myeloid malignancy: KIR ligand mismatch and outcome.
Weisdorf D; Cooley S; Devine S; Fehniger TA; DiPersio J; Anasetti C; Waller EK; Porter D; Farag S; Drobyski W; Defor T; Haagenson M; Curtsinger J; Miller J
Biol Blood Marrow Transplant; 2012 Jun; 18(6):937-43. PubMed ID: 22155505
[TBL] [Abstract][Full Text] [Related]
16. CD56-enriched donor cell infusion after post-transplantation cyclophosphamide for haploidentical transplantation of advanced myeloid malignancies is associated with prompt reconstitution of mature natural killer cells and regulatory T cells with reduced incidence of acute graft versus host disease: A pilot study.
Jaiswal SR; Zaman S; Nedunchezhian M; Chakrabarti A; Bhakuni P; Ahmed M; Sharma K; Rawat S; O'donnell P; Chakrabarti S
Cytotherapy; 2017 Apr; 19(4):531-542. PubMed ID: 28131632
[TBL] [Abstract][Full Text] [Related]
17. Donor Selection Based on Killer Cell Immunoglobulin-Like Receptor (KIR) Genotype May Improve Outcome After T-Cell-Replete Haploidentical Transplantation.
Torío A; Pascual MJ; Vidales I; Ortiz M; Caballero A; Heiniger AI
Transplant Proc; 2018 Mar; 50(2):679-682. PubMed ID: 29579887
[TBL] [Abstract][Full Text] [Related]
18. Impact of KIR-ligand mismatch on pediatric T-cell acute lymphoblastic leukemia in unrelated cord blood transplantation.
Kawahara Y; Ishimaru S; Tanaka J; Kako S; Hirayama M; Kanaya M; Ishida H; Sato M; Kobayashi R; Kato M; Goi K; Saito S; Koga Y; Hashii Y; Kato K; Sato A; Atsuta Y; Sakaguchi H
Transplant Cell Ther; 2022 Sep; 28(9):598.e1-598.e8. PubMed ID: 35660064
[TBL] [Abstract][Full Text] [Related]
19. Impact of incompatible killer cell immunoglobulin-like receptor and its ligand on the outcome of haploidentical bone marrow transplantation.
Duan LN; Han HX; Liu J; Yan HM; Zhu L; Xue M; Ding L; Zhu PY; Wang HX; Ji SQ
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2007 Aug; 15(4):809-15. PubMed ID: 17708809
[TBL] [Abstract][Full Text] [Related]
20. Phase II Study of Haploidentical Natural Killer Cell Infusion for Treatment of Relapsed or Persistent Myeloid Malignancies Following Allogeneic Hematopoietic Cell Transplantation.
Shaffer BC; Le Luduec JB; Forlenza C; Jakubowski AA; Perales MA; Young JW; Hsu KC
Biol Blood Marrow Transplant; 2016 Apr; 22(4):705-709. PubMed ID: 26772158
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]